Home - Eiger Biopharmaceuticals | Eiger Biopharmaceuticals

Eiger Announces Both Lonafarnib-based Treatments in Pivotal Phase 3 D-LIVR Trial in Hepatitis Delta Virus (HDV) Achieved Statistical Significance Against Placebo in Composite Primary Endpoint

Click here to read the press release.

ABOUT US

Developing and commercializing first-in-class, well-characterized drugs for life-threatening, rare and serious diseases with high unmet medical needs and no approved therapies.

In The News

March 16, 2023

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Phase 3 HDV D-LIVR (lonafarnib/ritonavir) Study: Pre-NDA Meeting Planned by End of Q2 Phase 3 HDV LIMT-2 (peginterferon lambda) Study: On Track to Complete Randomization by End of Q2 Phase 3 HI AVANT (avexitide) Program: Startup Activities Initiated Cash Position: $98.9 million in Cash, Cash

February 8, 2023

New England Journal of Medicine Publishes Positive Phase 3 TOGETHER Results with Peginterferon Lambda in COVID-19

- Phase 3 TOGETHER data showed early treatment with a single dose of peginterferon lambda (Lambda) in patients with mild-to-moderate COVID-19 infections resulted in significantly decreased clinical events - Lambda reduced risk of hospitalization or emergency room visits by 51% (primary endpoint)

December 15, 2022

Eiger BioPharmaceuticals Announces Leadership Change

President and CEO David A. Cory resigns from the company effective immediately Dr. David Apelian named Interim CEO PALO ALTO, Calif. --(BUSINESS WIRE)--Dec. 15, 2022-- Eiger BioPharmaceuticals, Inc. (“Eiger” or “the company”) (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on

SEE ALL

Innovative Therapies forHepatitis Delta Virusand Other Serious Diseases

<img decoding="async" class="alignright wp-image-2242 size-full" src="https://www.eigerbio.com/wp-content/uploads/2022/12/Eiger-DLIVR-Logo-small.png" alt="D-LIVR" width="300" height="106" align="right" />